SR0018LRB103 25958 MST 52310 r

1
SENATE RESOLUTION

 
2    WHEREAS, The substance use and opioid use crises in
3Illinois are responsible for historically high rates of
4overdoses and overdose-related fatalities; and
 
5    WHEREAS, According to the State's own opioid data, use and
6misuse of opioids in Illinois also continues to have
7substantial associated public health consequences, including
8increased rates of infectious diseases such as hepatitis C and
9HIV, lost productivity in the workplace, crime, neonatal
10abstinence syndrome, and homelessness; and
 
11    WHEREAS, The purpose of many federal programs is to
12provide resources to states for increasing access to
13FDA-approved medications for the treatment of substance use
14and opioid use disorder and for supporting the continuum of
15prevention, harm reduction, treatment, and recovery support
16services for opioid use disorder and other substance use
17disorders; and
 
18    WHEREAS, A prescription digital therapeutic is approved,
19cleared, or classified by the Food and Drug Administration
20under section 510(k), 513(f), or 515 of the Federal Food,
21Drug, and Cosmetic Act, and requires a prescription under
22section 801.109 of title 21 of the Code of Federal Regulations

 

 

SR0018- 2 -LRB103 25958 MST 52310 r

1(or any successor regulation); and
 
2    WHEREAS, Prescription digital therapeutics have the
3potential to significantly improve health care delivery to
4underserved populations because they transcend care access
5limitations due to geography, socioeconomic status, trust of
6traditional institutions, and more; and
 
7    WHEREAS, Clinical studies have shown significantly greater
8odds of stimulant and opioid abstinence during treatment if
9treatment as usual is combined with an FDA-authorized PDT that
10has both cognitive behavioral therapy and contingency
11management; and
 
12    WHEREAS, A 2018 study demonstrated that when a Community
13Reinforcement Approach and Contingency Management are
14administered together then a patient is 2.84 times more likely
15to remain abstinent at the end of the treatment than those in
16other programs; and
 
17    WHEREAS, The White House's Office of National Drug Control
18Policy recently released its 2022 National Drug Control
19Strategy document; specifically, the document points to
20prescription digital therapeutics and how these tools could
21help increase services for a wide array of patients; and
 

 

 

SR0018- 3 -LRB103 25958 MST 52310 r

1    WHEREAS, Federally-funded programs help many states to
2fund access to FDA-authorized PDTs for patients and providers;
3therefore, be it
 
4    RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL
5ASSEMBLY OF THE STATE OF ILLINOIS, that we urge the Department
6of Human Services and the Governor's Opioid Overdose
7Prevention and Recovery Steering Committee to closely consider
8funding FDA-authorized PDTs to help patients who are
9struggling with substance use and opioid use disorders; and be
10it further
 
11    RESOLVED, That a suitable copy of this resolution be
12delivered to the Secretary of the Illinois Department of Human
13Services.